Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Vulvar Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(24)
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 expression
Vulvar Cancer
PD-L1 expression
Vulvar Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
NTRK3 fusion
Vulvar Cancer
NTRK3 fusion
Vulvar Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Vulvar Cancer
NTRK2 fusion
Vulvar Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Vulvar Cancer
NTRK1 fusion
Vulvar Cancer
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Vulvar Cancer
NTRK3 fusion
Vulvar Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Vulvar Cancer
NTRK2 fusion
Vulvar Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Vulvar Cancer
NTRK1 fusion
Vulvar Cancer
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
MSI-H/dMMR
Vulvar Cancer
MSI-H/dMMR
Vulvar Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
TMB-H
Vulvar Cancer
TMB-H
Vulvar Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
GC
Sensitive: A2 - Guideline
GC
Sensitive
:
A2
GC
Sensitive: A2 - Guideline
GC
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
erlotinib
Sensitive: A2 - Guideline
erlotinib
Sensitive
:
A2
erlotinib
Sensitive: A2 - Guideline
erlotinib
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
CP
Sensitive: A2 - Guideline
CP
Sensitive
:
A2
CP
Sensitive: A2 - Guideline
CP
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
FP
Sensitive: A2 - Guideline
FP
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
5-fluorouracil + mitomycin
Sensitive: A2 - Guideline
5-fluorouracil + mitomycin
Sensitive
:
A2
5-fluorouracil + mitomycin
Sensitive: A2 - Guideline
5-fluorouracil + mitomycin
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
capecitabine + mitomycin
Sensitive: A2 - Guideline
capecitabine + mitomycin
Sensitive
:
A2
capecitabine + mitomycin
Sensitive: A2 - Guideline
capecitabine + mitomycin
Sensitive
:
A2
No biomarker
Vulvar Cancer
No biomarker
Vulvar Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
PD-L1 negative
Vulvar Cancer
PD-L1 negative
Vulvar Cancer
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
PD-L1 overexpression
Vulvar Cancer
PD-L1 overexpression
Vulvar Cancer
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login